IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL
Codo P, Eigentler T, Heinzerling L, Krauss J, Weishaupt C, Ochsenreither S, Lebbe C, Mohr P, Oliva M, Oberoi H, Terheyden P, Perez JT, Bauernfeind FG, Fluck M, Richtig E, Soria A, Gonzalez M, Funkner F, Wengenmayer P, Vahrenhorst D, Seibel T, Quintini G, Schmitt-Bormann B, Scheel B, Falk M, Gnad-Vogt U (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: BMJ PUBLISHING GROUP
City/Town: LONDON
Pages Range: A502-A502
Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER
DOI: 10.1136/jitc-2021-SITC2021.473
Abstract
CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system.1 2 An ongoing phase I trial is investigating the intratumoral (i.t.) administration of CV8102 in patients with advanced cutaneous melanoma (cMEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) and adenoid cystic carcinoma (ACC), either as a single agent or in combination with systemic anti-PD-1 antibodies. Preliminary immune profiling results will be reported.
Authors with CRIS profile
Involved external institutions
CureVac GmbH
Germany (DE)
Hospital Universitario Ramón y Cajal
Spain (ES)
Hospital Universitario Virgen de la Victoria
Spain (ES)
Universitätsklinikum Bonn
Germany (DE)
Catalan Institute of Oncology / Institut Català d'Oncologia (ICO)
Spain (ES)
Fachklinik Hornheide
Germany (DE)
Elbe Kliniken Stade-Buxtehude
Germany (DE)
Assistance Publique-Hôpitaux de Paris (AP-HP)
France (FR)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Universität zu Lübeck
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Westfälische Wilhelms-Universität (WWU) Münster
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
Germany (DE)
Hospital Universitario Ramón y Cajal
Spain (ES)
Hospital Universitario Virgen de la Victoria
Spain (ES)
Universitätsklinikum Bonn
Germany (DE)
Catalan Institute of Oncology / Institut Català d'Oncologia (ICO)
Spain (ES)
Fachklinik Hornheide
Germany (DE)
Elbe Kliniken Stade-Buxtehude
Germany (DE)
Assistance Publique-Hôpitaux de Paris (AP-HP)
France (FR)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Universität zu Lübeck
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Westfälische Wilhelms-Universität (WWU) Münster
Germany (DE)
Deutsches Krebsforschungszentrum (DKFZ)
Germany (DE)
Universitätsklinikum Tübingen
Germany (DE)
How to cite
APA:
Codo, P., Eigentler, T., Heinzerling, L., Krauss, J., Weishaupt, C., Ochsenreither, S.,... Gnad-Vogt, U. (2021). IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A502-A502). LONDON: BMJ PUBLISHING GROUP.
MLA:
Codo, Paula, et al. "IMMUNE PROFILING OF PATIENTS WITH ADVANCED SOLID TUMORS TREATED WITH INTRATUMORALLY ADMINISTERED CV8102 AS A SINGLE-AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODIES IN PHASE I CLINICAL TRIAL." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A502-A502.
BibTeX: Download